Tag Archives: HELIOS-B

Insulet Hires New CEO; Galmed Sublingual Semaglutide; Vutrisiran ATTR-CM CHMP Opinion 

Three cardiometabolic-related news items have been observed: Ashley McEvoy has been appointed as Insulet’s new CEO (view press release); Galmed announced an agreement with Entomus for sublingual semaglutide development (view press release); and CHMP adopted a positive opinion for the vutrisiran ATTR-CM indication (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here

ATTD 2025 Key Press Releases (March 21)  

On the third day of ATTD 2025, five cardiometabolic-related news items have been observed from Novo Nordisk, Skye Bioscience, Terns Pharmaceuticals, Allurion Technologies, and Alnylam Pharmaceuticals. Below, FENIX provides highlights and insights for the respective news items. 

This content is for Read Less members only.
Register
Already a member? Log in here